Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Dasatinib-based Combination Therapy in Ph+ ALL and Ph+ MPAL
NCT04872790Phase 1Active, not recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Sep 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in acute lymphoblastic leukemia (ALL) and mixed phenotype acute leukemia (MPAL), sponsored by OHSU Knight Cancer Institute. Primary endpoints: Incidence of dose-limiting toxicities at Day 32 and Incidence of adverse events. Started Sep 2022; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT04872790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04872790.